Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015
Authors' conclusion
AOM use was inversely associated with incident CVD among ORCa survivors and cancer-free women. Further studies of second-generation AOM, particularly glucagon-like peptide-1 receptor agonists, are warranted.
Study context
- Population
- Women aged ≥65 years: Obesity-related cancers (ORCa) survivors and age- and index-matched cancer-free women; SEER-Medicare 2007–2015matched cohort · ORCa survivors 23,276 · index-matched cancer-free women 23,276
- Participants
- 46,552 women
- Exposure
- Antiobesity medications (AOM) use vs no AOM use
- Outcome
- Incident CVD
Methodological detailsSEER-Medicare, age- and index-matched, multivariable Cox proportional hazards models
- SEER-Medicare
- Age- and index-matched
- Multivariable Cox proportional hazards models
Main finding
As reported in the abstract
Incident CVD, ITT analysis
AOM use vs No AOM useHazard ratio (95% CI)
Composite analytic sample
0.80(0.71–0.90)
Cancer-free women
0.70(0.58–0.85)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Incident CVD, per-protocol analysisAOM usevs No AOM useORCa survivors · per-protocol | 0.74 (0.57–0.94) | |
| Incident CVD, per-protocol analysisAOM usevs No AOM useCancer-free women · per-protocol | 0.59 (0.45–0.77) | |
| 0.512Hazard ratio (log scale) |
Incident cardiovascular disease (CVD), per-protocol analysis
- Associations more pronounced within the first 2 years of follow-up
Original publication
Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015. Obesity (Silver Spring). Published 4 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →